TY - JOUR T1 - Kidney function on admission predicts in-hospital mortality in COVID-19 JF - medRxiv DO - 10.1101/2020.06.18.20134627 SP - 2020.06.18.20134627 AU - Sinan Trabulus AU - Cebrail Karaca AU - İlker İnanç Balkan AU - Mevlüt Tamer Dincer AU - Ahmet Murt AU - Şeyda Gül Özcan AU - Rıdvan Karaali AU - Bilgül Mete AU - Alev Bakır AU - Mert Ahmet Kuşkucu AU - Mehmet Rıza Altıparmak AU - Fehmi Tabak AU - Nurhan Seyahi Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/20/2020.06.18.20134627.abstract N2 - Background Recent data have reinforced the concept of a reciprocal relationship between COVID-19 and kidney function. However, most studies have focused on the effect of COVID-19 on kidney function, whereas data regarding kidney function on the COVID-19 prognosis is scarce. Therefore, in this study, we aimed to investigate the association between eGFR on admission and the mortality rate of COVID-19.Methods We recruited 336 adult consecutive patients (male 57.1%, mean age 55.0±15.9) that were hospitalized with the diagnosis of COVID-19 in the tertiary care university hospital. Data were collected from the electronic health records of the hospital. On admission, eGFR was calculated using the CKD-EPI formula. Acute kidney injury was defined according to the KDIGO criteria. Binary logistic regression and Cox regression analyses were used to assess the relationship between eGFR on admission and in-hospital mortality of COVID-19.Results Baseline eGFR was under 60 mL/min/1.73m2 in 61 patients (18.2%). Acute kidney injury occurred in 29.1% of the patients. In-hospital mortality was calculated as 12.8%. Age-adjusted and multivariate logistic regression analysis (p:0.005, odds ratio:0.974, CI:0.956-0.992) showed that baseline eGFR was independently associated with mortality. Additionally, age-adjusted Cox regression analysis revealed a higher mortality rate in patients with an eGFR under 60 mL/min/1.73m2.Conclusions On admission eGFR seems to be a prognostic marker for mortality in patients with COVID-19; We recommend to determine eGFR in all patients on admission and use it as an additional tool for risk stratification. Close follow-up should be warranted in patients with reduced eGFR.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe did not receive external funding.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty Ethical Committee (approval no: 2020-56318).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI confirm that all data referred to in the manuscript are available. ER -